3rd Qtr/9 Mths Results 2 of 2

AstraZeneca PLC 24 October 2001 PART 2 Consolidated Profit & Loss Account For Continuing Operations 2001 2000 For the nine months ended 30 September $m $m Sales 12,040 11,660 Cost of sales (3,250) (3,045) Distribution costs (89) (168) Research and development (1,955) (1,842) Selling, general and administrative expenses (3,984) (3,715) Other operating income 304 123 Operating profit before exceptional items 3,066 3,013 Exceptional items charged to operating profit (126) (222) Operating profit 2,940 2,791 Share of joint ventures' and associates' operating - 7 profits Profit on sale of fixed assets 10 - Net interest and dividend income 101 56 Profit on ordinary activities before taxation 3,051 2,854 Profit before taxation before exceptional items 3,167 3,076 Exceptional items charged to profit before taxation (116) (222) Taxation (836) (849) Profit on ordinary activities after taxation 2,215 2,005 Attributable to minorities (7) (10) Net profit for the period 2,208 1,995 Dividends to Shareholders (405) (406) Profit retained for the period 1,803 1,589 Earnings per Ordinary Share before exceptional items $1.30 $1.23 Earnings per Ordinary Share $1.25 $1.13 Diluted earnings per Ordinary Share $1.25 $1.13 Weighted average number of Ordinary Shares in issue 1,762 1,769 (millions) Diluted average number of Ordinary Shares in issue 1,764 1,771 (millions) Consolidated Profit & Loss Account For Continuing Operations 2001 2000 For the quarter ended 30 September $m $m Sales 3,950 3,797 Cost of sales (1,064) (961) Distribution costs (29) (48) Research and development (614) (631) Selling, general and administrative expenses (1,324) (1,242) Other operating income 96 52 Operating profit before exceptional items 1,015 967 Exceptional items charged to operating profit (45) (43) Operating profit 970 924 Share of joint ventures' and associates' operating - (12) profits Profit on sale of fixed assets - - Net interest and dividend income 23 22 Profit on ordinary activities before taxation 993 934 Profit before taxation before exceptional items 1,038 977 Exceptional items charged to profit before taxation (45) (43) Taxation (271) (275) Profit on ordinary activities after taxation 722 659 Attributable to minorities (2) (5) Net profit for the period 720 654 Dividends to Shareholders - - Profit retained for the period 720 654 Earnings per Ordinary Share before exceptional items $0.43 $0.39 Earnings per Ordinary Share $0.41 $0.37 Diluted earnings per Ordinary Share $0.41 $0.37 Weighted average number of Ordinary Shares in issue 1,757 1,766 (millions) Diluted average number of Ordinary Shares in issue 1,759 1,768 (millions) Consolidated Balance Sheet 2001 2000 As at 30 September $m $m Fixed assets 7,929 9,281 Current assets 10,581 11,166 Total Assets 18,510 20,447 Creditors due within one year (6,391) (7,236) Net current assets 4,190 3,930 Total assets less current liabilities 12,119 13,211 Creditors due after more than one year (909) (1,169) Provisions for liabilities and charges (1,075) (1,216) Net assets 10,135 10,826 Capital and reserves Shareholders' funds and minority interests 10,135 10,826 Consolidated Cash Flow Statement 2001 2000 For the nine months ended 30 September $m $m Cash flow from operating activities Operating profit before exceptional items 3,066 3,365 Depreciation and amortisation 633 773 Increase in working capital and other non-cash movements (436) (186) Net cash inflow from operating activities before exceptional items 3,263 3,952 Outflow related to exceptional items (280) (623) Net cash inflow from operating activities 2,983 3,329 Returns on investments and servicing of finance 137 (10) Tax paid (631) (587) Capital expenditure and financial investment (990) (1,001) Acquisitions and disposals (44) - Equity dividends paid to Shareholders (830) (820) Net cash inflow before management of liquid resources and financing 625 911 Net (purchase)/issues of shares (702) (340) Exchange and other movements (51) (159) (Decrease)/increase in net cash funds in the period (128) 412 Net cash funds at beginning of period 3,605 2,169 Net cash funds at end of period 3,477 2,581 Notes to the Interim Financial Statements 1 BASIS OF PREPARATION AND ACCOUNTING POLICIES The unaudited results for the nine months ended 30 September 2001 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 2000 Annual Report and Form 20-F. In 2001, the continued standardisation of accounting treatments across AstraZeneca has led certain subsidiaries to classify as cost of sales some elements of expense recorded as distribution costs in previous periods. The effect of this change in the nine months to 30 September 2001 is to reclassify approximately $90m of costs. Previous periods have not been restated. These interim financial statements do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for AstraZeneca PLC for the year ended 31 December 2000 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985. 2 JOINT VENTURES AND ASSOCIATES The Group's share of joint ventures' sales for the nine months to 30 September 2001 amounted to $171m and $185m for the comparative period. Share of joint ventures' operating profits for the nine months to 30 September 2001 amounted to nil, and for the comparative period $7m. 3 ANALYSIS OF EXCEPTIONAL ITEMS CHARGED TO OPERATING PROFIT The following are the components of the exceptional charges to operating profits from continuing operations which relate to the integration and synergy programme commenced after the AstraZeneca merger: 2001 2000 For the nine months ended 30 September $m $m Cost of sales 7 4 Research and development 72 26 Selling, general and administrative expenses 47 192 126 222 4 NET CASH FUNDS The table below provides an analysis of net cash funds and a reconciliation of net cash flow to movement in net cash funds. At 31 Dec Cash Other Exchange At 30 Sept 2000 flow non-cash movements 2001 $m $m $m $m $m Loans due after 1 year (631) (22) - - (653) Current instalments of (88) (141) - (4) (233) loans Total loans (719) (163) - (4) (886) Short-term investments 3,429 689 - (50) 4,068 Cash 1,021 (620) - (10) 391 Overdrafts (113) 31 - 10 (72) Short-term borrowings, excluding overdrafts (13) (14) - 3 (24) 4,324 86 - (47) 4,363 Net cash funds 3,605 (77) - (51) 3,477 Issue of AstraZeneca PLC Ordinary Shares (72) Repurchase of AstraZeneca PLC Ordinary Shares 774 Net cash inflow before management of liquid resources and financing 625 5 NINE MONTHS PRODUCT SALES ANALYSIS World US Nine Nine Constant Nine Months Months Actual Currency Months Actual 2001 2000 Growth Growth 2001 Growth $m $m % % $m % Gastrointestinal: Losec 4,287 4,532 (5) (2) 2,846 (6) Nexium 295 4 n/m n/m 218 n/m Others 30 34 (12) (3) - - Total 4,612 4,570 1 4 3,064 1 Gastrointestinal Cardiovascular: Zestril 832 960 (13) (10) 494 (16) Seloken 554 405 37 42 350 76 Plendil 332 353 (6) (1) 134 - Tenormin 300 363 (17) (9) 43 (31) Atacand 289 196 47 56 105 44 Imdur 64 73 (12) (4) 8 (27) Others 250 285 (12) (5) 39 (24) Total Cardiovascular 2,621 2,635 (1) 4 1,173 5 Respiratory: Pulmicort 570 512 11 18 200 113 Rhinocort 194 165 18 22 127 34 Accolate 115 131 (12) (10) 83 (24) Oxis 94 84 12 22 - - Bricanyl 80 94 (15) (8) - - Symbicort 34 - n/m n/m - - Others 36 38 (5) 6 - - Total Respiratory 1,123 1,024 10 16 410 38 Oncology: Zoladex 519 553 (6) 1 154 (3) Nolvadex 446 405 10 13 335 20 Casodex 393 314 25 32 168 16 Arimidex 139 117 19 26 48 17 Others 22 22 - 9 - - Total Oncology 1,519 1,411 8 14 705 13 CNS: Seroquel 526 293 80 83 438 66 Zomig 209 178 17 21 118 7 Others 16 24 (33) (33) 5 (55) Total CNS 751 495 52 55 561 46 5 NINE MONTHS PRODUCT SALES ANALYSIS (CONTINUED) World US Nine Nine Constant Nine Months Months Actual Currency Months Actual 2001 2000 Growth Growth 2001 Growth $m $m % % $m % Pain, Infection and Other Pharma: Diprivan 329 393 (16) (11) 148 (18) Merrem 162 122 33 41 37 236 Xylocaine 155 175 (11) (4) 40 (11) Marcaine 61 67 (9) (2) 19 (14) Naropin 43 39 10 18 9 (10) Other Pharma Products 353 429 (18) (9) 110 (7) Total Pain, Infection and Other Pharma 1,103 1,225 (10) (3) 363 (6) Salick Health Care 144 135 7 7 144 7 Astra Tech 90 85 6 17 5 67 Marlow Foods 77 70 10 20 - - Other - 10 n/m n/m - - Total 12,040 11,660 3 8 6,425 8 n/m not meaningful 6 THIRD QUARTER PRODUCT SALES ANALYSIS World US 3rd 3rd Constant 3rd Quarter Quarter Actual Currency Quarter Actual 2001 2000 Growth Growth 2001 Growth $m $m % % $m % Gastrointestinal: Losec 1,421 1,565 (9) (6) 970 (9) Nexium 168 4 n/m n/m 138 n/m Others 9 12 (25) (17) - - Total 1,598 1,581 1 4 1,108 4 Gastrointestinal Cardiovascular: Zestril 188 299 (37) (34) 82 (55) Seloken 204 144 42 46 141 81 Plendil 120 120 - 5 57 8 Tenormin 87 110 (21) (12) 8 (38) Atacand 93 72 29 37 29 4 Imdur 19 24 (21) (13) 2 (50) Others 75 82 (9) - 12 (14) Total 786 851 (8) (3) 331 (11) Cardiovascular 6 THIRD QUARTER PRODUCT SALES ANALYSIS (CONTINUED) World US 3rd 3rd Constant 3rd Quarter Quarter Actual Currency Quarter Actual 2001 2000 Growth Growth 2001 Growth $m $m % % $m % Respiratory: Pulmicort 161 159 1 7 58 66 Rhinocort 64 51 25 29 46 44 Accolate 20 17 18 24 11 - Oxis 29 28 4 11 - - Bricanyl 25 28 (11) (4) - - Symbicort 20 - n/m n/m - - Others 10 12 (17) (17) - - Total Respiratory 329 295 12 18 115 47 Oncology: Zoladex 175 189 (7) - 52 (7) Nolvadex 160 130 23 27 125 44 Casodex 149 94 59 68 71 97 Arimidex 47 35 34 40 16 100 Others 7 7 - 14 - - Total Oncology 538 455 18 25 264 41 CNS: Seroquel 169 89 90 93 137 78 Zomig 55 46 20 27 18 (22) Others 13 6 n/m n/m 2 (33) Total CNS 237 141 68 72 157 52 Pain, Infection and Other Pharma: Diprivan 114 109 5 11 61 33 Merrem 56 44 27 34 15 150 Xylocaine 52 58 (10) (3) 14 (13) Marcaine 20 22 (9) - 7 (13) Naropin 14 12 17 25 4 - Other Pharma 105 134 (22) (9) 39 18 Products Total Pain, Infection and Other Pharma 361 379 (5) 4 140 24 Salick Health Care 49 45 9 9 49 9 Astra Tech 28 27 4 15 2 100 Marlow Foods 24 23 4 13 - - Other - - - - - - Total 3,950 3,797 4 9 2,166 10 n/m not meaningful 7 NINE MONTHS TERRITORIAL SALES ANALYSIS % Growth Nine Nine Months Months 2001 2000 Constant $m $m Actual Currency USA 6,425 5,976 8 8 Japan 591 581 2 17 France 701 662 6 16 Germany 511 528 (3) 6 Italy 457 417 10 20 Sweden 199 242 (18) (4) UK 551 603 (9) (1) Rest of World 2,605 2,651 (2) 6 Total 12,040 11,660 3 8 8 THIRD QUARTER TERRITORIAL SALES ANALYSIS % Growth 3rd 3rd Quarter Quarter 2001 2000 Constant $m $m Actual Currency USA 2,166 1,966 10 10 Japan 202 207 (2) 15 France 219 212 3 11 Germany 163 175 (7) 2 Italy 120 98 22 34 Sweden 57 70 (19) 1 UK 181 212 (15) (7) Rest of World 842 857 (2) 6 Total 3,950 3,797 4 9 Shareholder Information ANNOUNCEMENTS AND MEETINGS Annual Business Review - London 3 December 2001 - New York 5 December 2001 Announcement of 2001 Full Year Results 31 January 2002 Announcement of First Quarter Results 2002 and Annual General 25 April 2002 Meeting Announcement of Half Year Results 2002 25 July 2002 Announcement of Third Quarter Results 2002 24 October 2002 DIVIDENDS The record date for the first interim dividend paid on 5 October 2001 (in the UK, Sweden and the US) was 24 August 2001. Ordinary Shares traded ex-dividend on the London and Stockholm Stock Exchanges from 22 August 2001. ADRs traded ex-dividend on the New York Stock Exchange from the same date. The record date for the second interim dividend for 2001 payable on 8 April 2002 (in the UK, Sweden and the US) will be 22 February 2002. Ordinary Shares will trade ex-dividend on the London and Stockholm Stock Exchange from 20 February 2002. ADRs will trade ex-dividend on the New York Stock Exchange from the same date. Future dividends will normally be paid as follows: First interim Announced end of July and paid in October. Second interim Announced in January and paid in April. TRADE MARKS The following brand names used in this interim report are trade marks of the AstraZeneca group of companies: Accolate Arimidex Astra Tech Atacand Atacand HCT Atacand Plus Bricanyl Casodex Crestor Diprivan Faslodex Imdur Iressa Losec Marcaine Merrem Naropin Nexium Nolvadex Oxis Plendil Prilosec Pulmicort Pulmicort Respules Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL Xylocaine Zestril Zoladex Zomig Zomig Rapimelt Zomig ZMT ADDRESSES FOR CORRESPONDENCE Registrar and Depositary Registered Swedish Securities Transfer Office for ADRs Office Register Centre The AstraZeneca Morgan Guaranty 15 Stanhope VPC AB Registrar Trust Gate Box 7822 Lloyds TSB Company of New London S-103 97 Stockholm Registrars York W1K 1LN Sweden The Causeway ADR Service Worthing Center West Sussex PO Box 842006 BN99 6DA Boston, MA 02284-2006 Tel:(0870)600 3956 Tel:(781)575 4328 Tel:(020)7304 5000 Tel: (8) 402 9000 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability and the risks related to the difficulty of completing the integration of Astra's and Zeneca's large and complex businesses on a timely basis and realising synergies.

Companies

AstraZeneca (AZN)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today